Cathepsin D, a Lysosomal Protease, Regulates ABCA1-mediated Lipid Efflux*
暂无分享,去创建一个
R. S. Kiss | Y. Marcel | R. McPherson | Lea Sarov-Blat | B. Haidar | Christopher Harder | R. Brunet | Bassam Haidar
[1] V. Laurent-Matha,et al. Cathepsin D: newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. , 2006, Cancer letters.
[2] K. Blennow,et al. The Cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease , 2006, Human mutation.
[3] A. Lehesjoki,et al. Cathepsin D deficiency underlies congenital human neuronal ceroid-lipofuscinosis. , 2006, Brain : a journal of neurology.
[4] S. Sonnino,et al. Saposin B binds and transfers phospholipids Published, JLR Papers in Press, February 6, 2006. , 2006, Journal of Lipid Research.
[5] H. McBride,et al. The Lipoprotein Receptor-related Protein-1 (LRP) Adapter Protein GULP Mediates Trafficking of the LRP Ligand Prosaposin, Leading to Sphingolipid and Free Cholesterol Accumulation in Late Endosomes and Impaired Efflux* , 2006, Journal of Biological Chemistry.
[6] Y. Dobashi,et al. Overexpression in colorectal carcinoma of two lysosomal enzymes, CLN2 and CLN1, involved in neuronal ceroid lipofuscinosis , 2006, Cancer.
[7] G. Johnson,et al. A mutation in the cathepsin D gene (CTSD) in American Bulldogs with neuronal ceroid lipofuscinosis. , 2006, Molecular genetics and metabolism.
[8] C. Eng,et al. Genetic variation of PLTP modulates lipoprotein profiles in hypoalphalipoproteinemia Published, JLR Papers in Press, December 30, 2005. , 2006, Journal of Lipid Research.
[9] P. Tontonoz,et al. Liver X receptors as integrators of metabolic and inflammatory signaling. , 2006, The Journal of clinical investigation.
[10] J. Villadangos,et al. Destructive potential of the aspartyl protease cathepsin D in MHC class II‐restricted antigen processing , 2005, European journal of immunology.
[11] V. Vetvicka,et al. Dual role of cathepsin D: ligand and protease. , 2005, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.
[12] I. Gelissen,et al. Glycosphingolipid Accumulation Inhibits Cholesterol Efflux via the ABCA1/Apolipoprotein A-I Pathway , 2005, Journal of Biological Chemistry.
[13] M. Elleder,et al. Prosaposin deficiency -- a rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient. , 2005, Neuropediatrics.
[14] H. Grosch,et al. Purified recombinant human prosaposin forms oligomers that bind procathepsin D and affect its autoactivation. , 2004, The Biochemical journal.
[15] Jonathan C. Cohen,et al. Multiple Rare Alleles Contribute to Low Plasma Levels of HDL Cholesterol , 2004, Science.
[16] R. Desnick,et al. Lipid abnormalities in children with types A and B Niemann Pick disease. , 2004, The Journal of pediatrics.
[17] R. Dwek,et al. Accumulation of Glycosphingolipids in Niemann-Pick C Disease Disrupts Endosomal Transport* , 2004, Journal of Biological Chemistry.
[18] H. Chapman,et al. Cathepsins as transcriptional activators? , 2004, Developmental cell.
[19] J. Genest,et al. Apolipoprotein A-I Activates Cellular cAMP Signaling through the ABCA1 Transporter* , 2004, Journal of Biological Chemistry.
[20] C. Peters,et al. Cathepsin L is involved in cathepsin D processing and regulation of apoptosis in A549 human lung epithelial cells , 2004, Biological chemistry.
[21] S. Witting,et al. Ceramide Enhances Cholesterol Efflux to Apolipoprotein A-I by Increasing the Cell Surface Presence of ATP-binding Cassette Transporter A1* , 2003, Journal of Biological Chemistry.
[22] V. Puri,et al. Sphingolipid Storage Induces Accumulation of Intracellular Cholesterol by Stimulating SREBP-1 Cleavage* , 2003, Journal of Biological Chemistry.
[23] R. Pagano. Endocytic trafficking of glycosphingolipids in sphingolipid storage diseases. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[24] K. Sandhoff,et al. Biosynthesis and degradation of mammalian glycosphingolipids. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.
[25] R. Dwek,et al. Glucosylceramide modulates membrane traffic along the endocytic pathway Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200232-JLR200 , 2002, Journal of Lipid Research.
[26] R. Dwek,et al. Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein E levels by glycosphingolipids. , 2002, Biochemical and biophysical research communications.
[27] C. Isidoro,et al. Endosomal-Lysosomal Proteolysis Mediates Death Signalling by TNFα, Not by Etoposide, in L929 Fibrosarcoma Cells: Evidence for an Active Role of Cathepsin D , 2002, Biological chemistry.
[28] A. Tall,et al. Acid Sphingomyelinase-deficient Macrophages Have Defective Cholesterol Trafficking and Efflux* , 2001, The Journal of Biological Chemistry.
[29] A. Remaley,et al. Cellular Localization and Trafficking of the Human ABCA1 Transporter* 210 , 2001, The Journal of Biological Chemistry.
[30] J. Brady,et al. Analysis of Glomerulosclerosis and Atherosclerosis in Lecithin Cholesterol Acyltransferase-deficient Mice* , 2001, The Journal of Biological Chemistry.
[31] M. Elleder,et al. A novel mutation in the coding region of the prosaposin gene leads to a complete deficiency of prosaposin and saposins, and is associated with a complex sphingolipidosis dominated by lactosylceramide accumulation. , 2001, Human molecular genetics.
[32] R. Kinscherf,et al. Ceramide induces aSMase expression: implications for oxLDL-induced apoptosis , 2001 .
[33] J. Genest,et al. Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations. , 2000, Atherosclerosis.
[34] A. Tall,et al. Phospholipid transfer protein gene knock-out mice have low high density lipoprotein levels, due to hypercatabolism, and accumulate apoA-IV-rich lamellar lipoproteins. , 2000, Journal of lipid research.
[35] P. Denéfle,et al. Human ATP-binding cassette transporter 1 (ABC1): genomic organization and identification of the genetic defect in the original Tangier disease kindred. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[36] C. Sensen,et al. Mutations in the ABC 1 gene in familial HDL deficiency with defective cholesterol efflux , 1999, The Lancet.
[37] A. Vaughan,et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. , 1999, The Journal of clinical investigation.
[38] V. Puri,et al. Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases , 1999, Nature Cell Biology.
[39] W. Schneider-Brachert,et al. Cathepsin D targeted by acid sphingomyelinase‐derived ceramide , 1999, The EMBO journal.
[40] A. von Eckardstein,et al. Apolipoprotein A-I(R151C)Paris is defective in activation of lecithin:cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux , 1999, Journal of Molecular Medicine.
[41] T. Langmann,et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease , 1999, Nature Genetics.
[42] J. Piette,et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1 , 1999, Nature Genetics.
[43] C. Sensen,et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency , 1999, Nature Genetics.
[44] T. Langmann,et al. Molecular cloning of the human ATP-binding cassette transporter 1 (hABC1): evidence for sterol-dependent regulation in macrophages. , 1999, Biochemical and biophysical research communications.
[45] A. Tall,et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. , 1999, The Journal of clinical investigation.
[46] A. von Eckardstein,et al. Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers. , 1999, Journal of lipid research.
[47] G. Luc,et al. Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORalpha. , 1998, Circulation.
[48] J. Ordovás,et al. β-glucocerebrosidase gene locus as a link for Gaucher's disease and familial hypo-α-lipoproteinaemia , 1998, The Lancet.
[49] M. Tremblay,et al. Familial HDL deficiency characterized by hypercatabolism of mature apoA-I but not proapoA-I. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[50] J. Virtamo,et al. Molecular Genetic Study of Finns With Hypoalphalipoproteinemia and Hyperalphalipoproteinemia A Novel Gly230Arg Mutation (LCATFin) of Lecithin:Cholesterol Acyltransferase (LCAT) Accounts for 5% of Cases With Very Low Serum HDL Cholesterol Levels , 1998 .
[51] A. von Eckardstein,et al. A natural apolipoprotein A-I variant, apoA-I (L141R)Pisa, interferes with the formation of alpha-high density lipoproteins (HDL) but not with the formation of pre beta 1-HDL and influences efflux of cholesterol into plasma. , 1997, Journal of lipid research.
[52] G. Luc,et al. Fish-eye disease: structural and in vivo metabolic abnormalities of high-density lipoproteins. , 1997, Metabolism: clinical and experimental.
[53] N. Maeda,et al. Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. , 1996, Human molecular genetics.
[54] K. Sandhoff,et al. Topology of glycosphingolipid degradation. , 1996, Trends in cell biology.
[55] M. Sheikh,et al. Retinoid regulation of human cathepsin D gene expression , 1996, The Journal of Steroid Biochemistry and Molecular Biology.
[56] B. Troen,et al. Regulation of cathepsin D gene expression in HL-60 cells by retinoic acid and calcitriol. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[57] F. May,et al. The human cathepsin D-encoding gene is transcribed from an estrogen-regulated and a constitutive start point. , 1993, Gene.
[58] Y. Kishimoto,et al. Saposins: structure, function, distribution, and molecular genetics. , 1992, Journal of lipid research.
[59] K. Sandhoff,et al. Activator proteins and topology of lysosomal sphingolipid catabolism. , 1992, Biochimica et biophysica acta.
[60] H. Grosch,et al. Molecular organization of the human cathepsin D gene. , 1991, DNA and cell biology.
[61] Y. Kishimoto,et al. Saposin proteins: structure, function, and role in human lysosomal storage disorders , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[62] G. Conner. Isolation of procathepsin D from mature cathepsin D by pepstatin affinity chromatography. Autocatalytic proteolysis of the zymogen form of the enzyme. , 1989, The Biochemical journal.
[63] R. Fagerstrom,et al. Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease , 1984, Clinical genetics.
[64] R. Dean. Direct evidence of importance of lysosomes in degradation of intracellular proteins , 1975, Nature.
[65] W. J. Dyer,et al. A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.
[66] R. Andrzejak,et al. Cathepsin D expression in human colorectal cancer: relationship with tumour type and tissue differentiation grade. , 2005, Journal of experimental therapeutics & oncology.
[67] J. Genest,et al. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[68] H. Rochefort,et al. Cathepsin D gene is controlled by a mixed promoter, and estrogens stimulate only TATA-dependent transcription in breast cancer cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.